Who are Psilocybin (Usona Institute)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Risperdal,reminyl, Any FDA approved antipsychotic agent, paliperidone clozapine, Quetiapine or Risperidone + Aripiprazole, risperidone (Risperdal), Trazodone + PAP therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/psilocybin-usona-institute.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Psilocybin (Usona Institute) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Psilocybin (Usona Institute) (Psilocybin (Usona Institute)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Psychiatry.

phase 3 5-HT2A receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Psilocybin (Usona Institute) (Psilocybin (Usona Institute)) — James J. Peters Veterans Affairs Medical Center. Psilocybin acts as a serotonin receptor agonist, specifically targeting the 5-HT2A receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Psilocybin (Usona Institute) TARGET	Psilocybin (Usona Institute)	James J. Peters Veterans Affairs Medical Center	phase 3		5-HT2A receptor
Risperdal,reminyl	Risperdal,reminyl	Jinan Mental Hospital	marketed	Atypical antipsychotic (Risperdal); Cholinesterase inhibitor (Reminyl)	Dopamine D2 receptor, serotonin 5-HT2A receptor (Risperdal); Acetylcholinesterase (Reminyl)
Any FDA approved antipsychotic agent	Any FDA approved antipsychotic agent	Vanguard Research Group	marketed	Antipsychotic (dopamine antagonist)	Dopamine D2 receptor (primary); serotonin 5-HT2A receptor and others (varies by agent)
paliperidone clozapine	paliperidone clozapine	Universidad Nacional de Rosario	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Quetiapine or Risperidone + Aripiprazole	Quetiapine or Risperidone + Aripiprazole	Otsuka Pharmaceutical Development & Commercialization, Inc.	marketed	Atypical antipsychotic	Dopamine D2 receptor, serotonin 5-HT2A receptor
risperidone (Risperdal)	risperidone (Risperdal)	University of South Florida	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Trazodone + PAP therapy	Trazodone + PAP therapy	VA Office of Research and Development	marketed	Serotonin antagonist and reuptake inhibitor (SARI) + mechanical ventilation device	Serotonin transporter (SERT); serotonin 5-HT2A receptor antagonism

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Psilocybin (Usona Institute) — Competitive Intelligence Brief. https://druglandscape.com/ci/psilocybin-usona-institute. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab